Advertisement
Phase 3 TANDEM study may help pave way to first approval of a CETP inhibitor
Reassurance from the lipid outcomes trial with the highest percentage female enrollment to date
Newly identified pathway may explain the so-called niacin paradox
Inflammation found more predictive of events than LDL-C in pooled analysis of RCTs
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Findings bolster the oral drug as an option for primary and secondary prevention
Randomized controlled study undercuts unsubstantiated ‘heart health’ claims
Intermittent statin dosing & bempedoic acid refresh the mix of options
Dr. Steven Nissen shares his take
Advertisement
Advertisement